A Monks

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

P M O'Connor, Joany Jackman, I Bae et al. · PubMed · 1997 · 881 citations

P53 Status, Tumor Biology, National Cancer Institute +15

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

J S Lee, K Paull, Curtis Hose et al. · Molecular Pharmacology · 1994 · 339 citations

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

Mauricio Muleiro Álvarez, K Paull, A Monks et al. · Journal of Clinical Investigation · 1995 · 218 citations · Full text

Drug Target, Quantitative Pcr, Cancer Biology +16

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

Lin Wu, A M Smythe, Susanna Stinson et al. · PubMed · 1992 · 157 citations

Pathology, Anticancer Drug Screening, Multidrug-resistant Phenotype +17

Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells

G L Scheffer, Mariska C. de Jong, A Monks et al. · British Journal of Cancer · 2002 · 13 citations · Full text